9:00am - 5:00pm

Office Hours Mon. - Fri.


Call Us For Free Consultation




Latest Immunotherapy System Shows Hopeful Promise After FDA Approval

Latest Immunotherapy System Shows Hopeful Promise After FDA Approval

Latest Immunotherapy System Shows Hopeful Promise After FDA Approval

Latest Immunotherapy System Shows Hopeful Promise After FDA Approval

Latest Immunotherapy System Shows Hopeful Promise After FDA ApprovalRecent studies have combined chemotherapy drugs with electrical currents in the hope of a new non-invasive treatment for mesothelioma patients. The goal of this new non-invasive treatment is to shrink the mesothelioma tumors of such patients and, thus far, seems to have been successfully working for a group of patients. A mesothelioma lawyer at Goldberg, Persky & White P.C. can help you or a loved with mesothelioma claims against companies that exposed them to asbestos.

Positive Clinical Trials Results

New optimism towards an increased life-expectancy arises following the researcher’s release of the results from phase 2 STELLAR clinical trials. STELLAR, also known as the “EF-23 trial”, was designed by Novocure to test the efficacy and safety of a medical device derived for mesothelioma patients – also known as the TTF-100L “Tumor Treating Fields” (TTF) system. This treatment was also combined with six (6) rounds of first-line chemotherapy drugs along with the device.

According to their analysis, this therapy seems to have been working well thus far.

The single-arm study was conducted with approximately eighty patients from 12 different European academic & non-academic medical centers. For 18 hours a day, participants wore the TTF device, which was set at a frequency of 150 kHz, while receiving a combination of pemetrexed (ALIMTA) and either cisplatin or carboplatin – popular first-line chemotherapy drugs. 

For a portion of patients whose tumors did not show signs of shrinkage following chemotherapy, an additional TTF treatment was administered. Patient progression was then tracked for an average of 12.5 months by researchers. 

Among the patients who received the combination therapy, they had lived an average of 18.2 months – which, in comparison to using chemotherapy as a standalone treatment, is double the survival rate of a mesothelioma patient. Although the survival rate was 62% after a year, the number dropped to 42% by the second year.

The therapy prevented mesothelioma tumors progression for an average of 7.6 months among the 72 patients who were examined. More than half (approximately 56% of participants) eventually required additional care to prevent the development of the tumor.

How the Novocure TTF-100L™ System Works

The Food and Drug Administration (FDA) approved the TTF therapy for patients with pleural mesothelioma whose tumors are unresectable or inoperable in May. Worn on the upper torso, the device is primarily used to delay or interrupt cell division by alternating electrical currents.

It is believed that different frequencies can inhibit tumor growth and destroy existing cancer cells while protecting neighboring healthy cells, according to Novocure, the global oncology company that created TTF. 

Not only does the device does not appear to have any toxic side-effects, but the treatment is non-invasive and has been well-tolerated among patients. Only a mild skin rash has been reported by a small percentage of patients. 

Optimism Towards the Future of Mesothelioma Treatments

Although new, Novocure and TTF technology is displaying hopeful promise to patients who have been diagnosed with rare cancers such as pleural mesothelioma. In addition to mesothelioma, Novocure has also worked for creating treatments for other types of cancers. For instance, Novocure’s TTF product, Optune, was approved by the FDA in 2011 for the treatment of glioblastoma, an aggressive form of brain cancer. This approval was a large success for Novocure.

Pleural mesothelioma is a rare disease – in the United States, only about 3,300 people are diagnosed with this illness each year. Additionally, in most cases, tumors are inoperable, meaning that new, non-surgical treatment options are limited. 

Unfortunately, mesothelioma has no cure; however, this does not stop the researcher’s optimism towards finding new and beneficial cures. The FDA approval of NovoTTF-100L was quite promising, as it was the first new therapy available to patients with pleural mesothelioma in 15-years. While cancer centers in the United States are now training oncology employees to use their device, Novocure intends to continue studying its TTF technology in the hope of helping as many patients as possible. Speak with a West Virginia Mesothelioma lawyer at Goldberg, Persky & White P.C. at our West Virginia branch today!

Check out some recent press: